Maxygen (MAXY)
Add to Watchlists Create an AlertMAXY Key Stats
| Income Statement | |
| Revenue TTM | 30.01M |
| Revenue Quarterly YoY Growth | -50.00% |
| EPS Diluted TTM | 0.7455 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | 20.56M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -71033% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 65.59M |
| Enterprise Value | -15.27M |
| PE Ratio TTM | 3.166 |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 0.8346 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | |
| Return on Equity | 17.70% |
MAXY News
- Maxygen (MAXY) Narrows Q1 Loss Street Insider May 3
- Maxygen Reports First Quarter 2013 Financial Results Business Wire May 3
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, F... May 3
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, F... Mar 12
- Maxygen (MAXY) Narrows Q4 Loss to 6c/Share Street Insider Mar 12
- Maxygen Reports Fourth Quarter and Year End 2012 Financial Results Business Wire Mar 12
- Maxygen Announces Tax Treatment of 2012 Cash Distribution noodls Jan 30
- Maxygen Announces Tax Treatment of 2012 Cash Distribution Business Wire Jan 29
- MAXYGEN INC Files SEC form 8-K, Other Events Nov 16
- High-Performing Biotech Fund To Add Six Stocks, Drop Maxygen, Progenics Nov 12
MAXY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Maxygen is up 129.4% over the last year vs S&P 500 Total Return up 28.68%, ARCA biopharma down 3.41%, and Sangamo BioSciences up 68.17%.
MAXY Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these MAXY related companies
Pro Ratings for MAXY
Pro Report PDF for MAXY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Pro Strategies Featuring MAXY
Did Maxygen make it into our Pro Portfolio Strategies?
MAXY Profile
Sector: Healthcare
Industry: Biotechnology
Other MAXY Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MAXY | 2.36 | -0.01 | -0.42% | 65.59M |